CTOs on the Move

OmniSonics Medical Technologies

www.omnisonics.com

 
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Camtec

Camtec is a Cambridge, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medfusion

Medfusion, a Cary, NC-based company offers patient-provider communication solutions nationally to enable healthcare providers offer superior service to their patients while improving office efficiency and generating revenue.

Athletic Greens

Athletic Greens® supports gut health, immunity, energy, recovery, focus, aging, and more. Take control of your health routine and only take the supplements your body truly needs. Made in New Zealand. No artificial colors. Better absorption. Delivered t...

Kentucky Clinical Research

Kentucky Clinical Research is a Grayson, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.